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Abstract
Background: Implementation of precision oncology interventions poses several 
challenges to informed consent and patient education. This study assessed cancer 
patients’ understanding, expectations, and outcomes regarding participation in re-
search examining the impact of matched tumor and germline sequencing on their 
clinical care.
Methods: A total of 297 patients (mean age: 59 years; 50% female; 96% white) with 
refractory, metastatic cancer were surveyed, including 217 who completed surveys 
both before and after undergoing integrated whole exome and transcriptome se-
quencing as part of a larger clinical research study.
Results: At baseline, the vast majority of patients expected to receive several poten-
tial direct benefits from study participation, including written reports of sequencing 
findings (88%), greater understanding of the causes of their cancer (74%), and par-
ticipation in clinical trials for which sequencing results would make them eligible 
(84%). In most cases, these benefits were not realized by study completion. Despite 
explanations from study personnel to the contrary, most participants (67%‐76%) pre-
sumed that incidental germline sequencing findings relevant to noncancerous health 
conditions (eg, diabetes) would automatically be disclosed to them. Patients reported 
low levels of concern about study risks at baseline and low levels of regret about 
study participation at follow‐up.
Conclusions: Findings suggest that cancer patients participating in precision oncology 
intervention research have largely unfulfilled expectations of direct benefits related to 
their study participation. Increased focus on patient education to supplement the informed 
consent process may help manage patients’ expectations regarding the extent and likeli-
hood of benefits received as a result of undergoing genomic sequencing.
K E Y W O R D S
genome sequencing, informed consent, patient education, precision oncology
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1 |  BACKGROUND
Next‐generation sequencing is rapidly emerging as a prom-
ising approach in cancer treatment. Improved understand-
ing of somatic and germline aberrations involved in cancer 
pathology can inform selection of therapies tailored to the 
individual patient's underlying molecular lesions.1 Such 
interventions have already demonstrated utility in a small 
subset of cases of both adult and pediatric cancer,2,3 and 
significant public and private investments are being made 
in a precision oncology model of care for future cancer 
patients.4
For the promise of precision oncology to be realized, patients 
will need to understand its benefits, risks, and limitations prior 
to consenting to treatment. Yet integration of matched tumor 
and germline sequencing into clinical care presenting signifi-
cant challenges for patient education.5 For example, limitations 
in genetic literacy can complicate provider‐patient communica-
tion of the purpose and findings of biomarker‐based therapies.6 
Germline analyses can yield secondary or incidental results with 
health implications for both patients and family members, creat-
ing challenges for informed consent.7 Many current sequencing 
efforts are being used to identify clinical trials for which patients 
may be eligible, potentially blurring the line between research 
and clinical practice and giving rise to “therapeutic misconcep-
tions” among patients.8 These challenges suggest a need for re-
search to illuminate cancer patients’ appraisal and understanding 
of next‐generation sequencing, thereby informing future patient 
education and counseling efforts in this area.
Only a few investigations have explored patient perspec-
tives in the context of precision oncology. For example, stud-
ies have examined decisions whether or not to participate in 
cancer genome sequencing studies9 and perceived benefits 
of genomic tumor profiling.10 However, most studies in this 
area have been cross‐sectional in nature and/or with relatively 
small sample sizes. Furthermore, it is unclear whether and to 
what extent patients lack awareness of—or hold misconcep-
tions about—the use of genome sequencing to tailor treat-
ment recommendations. To help address this gap, we report 
here on a longitudinal survey of patients undergoing inte-
grated tumor and germline sequencing to inform treatment of 
their advanced or refractory cancer.
2 |  METHODS
2.1 | Overview
This paper reports on results from an ancillary study embed-
ded with the larger MI‐ONCOSEQ (Michigan Oncology 
Sequencing) program.11,12 Briefly, MI‐ONCOSEQ is a preci-
sion oncology research protocol at the University of Michigan 
Comprehensive Cancer Center. It expansively profiles ge-
netic aberrations of a patient's tumor through comparison to 
a matched normal sample. MI‐ONCOSEQ's approach allows 
for the identification of somatic and germline events, point 
mutations, amplifications, insertions/deletions, gene fusions, 
and outlier gene expression. Team members present sequenc-
ing results at an institutional precision medicine tumor board 
(PMTB) composed of members with expertise in medical on-
cology, hematology, clinical pathology, cancer genetics, ge-
netic counseling, bioinformatics, and bioethics. The PMTB 
discusses potentially actionable findings, with a summary test 
report ultimately e‐mailed to each referring oncologist within 
approximately 1 week of the PMTB meeting. Actionable 
findings typically involved tumor sequencing (ie, somatic) 
results that might inform care or confer eligibility for cancer 
treatment trials, but also included germline results that could 
inform cancer prevention efforts in participants’ blood rela-
tives.13 The referring oncologist then decides whether, how, 
and when to return sequencing results to patients and inte-
grate these findings into the treatment plan.
2.2 | Informed consent process 
for sequencing
A study team member met in person with each MI‐
ONCOSEQ participant to review the parent project's pur-
pose, procedures, and potential risks/benefits. The study's 
main goal was described as “to identify key genes impor-
tant to cancer cells that could potentially influence clinical 
decision making for managing cancer.” Participants were 
informed that they would always be told about sequencing 
results that “have a direct impact on care of your current 
cancer,” but that “the results are not guaranteed to help 
your doctor take care of you.” As part of the consent pro-
cess, participants chose whether or not they would want 
to receive secondary sequencing findings unrelated to the 
treatment of their current cancer, but that might inform 
future treatment of other cancers, either for themselves or 
blood relatives (eg, BRCA 1/2 mutations). Study participa-
tion length was considered indefinite, given that partici-
pants’ tumor tissue would be stored for potential future 
studies and might be used to create cell lines for ongo-
ing research that “may improve the lives of future patients 
with cancer.”
2.3 | Participants and survey procedures
We surveyed adult patients (n = 297) with advanced 
stage solid tumor malignancies who enrolled in the 
MI‐ONCOSEQ program from April 2014 to December 
2016. All patients participating in MI‐ONCOSEQ dur-
ing that timeframe were eligible for our survey study, and 
the survey study sample did not differ from the broader 
MI‐ONCOSEQ patient population in terms of key demo-
graphic variables. The University of Michigan Medical 
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School's Institutional Review Board (IRBMED) approved 
all study procedures. Surveys were administered at two 
time points: baseline and follow‐up. Study team members 
distributed baseline surveys in‐person to patients (response 
rate = 79%), after a study team member had obtained in-
formed consent for the project. Patients were asked to 
complete and return the baseline survey within 2 weeks by 
mail. A web survey option was made available for patients 
preferring that format. The study team mailed follow‐up 
surveys home to patients approximately 2 weeks after the 
referring oncologist received their sequencing results sur-
veys (n = 217; response rate = 76%). Some patients did 
not receive follow‐up surveys because their tumor biopsy 
material could not be properly analyzed (most follow‐up 
survey items presumed that the patient's sequencing report 
had been generated), or because they died in the period 
between the baseline and follow‐up surveys (see Figure 1 
for more description of the flow of study procedures and 
attrition over the course of the longitudinal survey).
2.4 | Measures
The patient surveys used both validated self‐report measures 
and questionnaire items created specifically for this study. 
We developed the latter with the assistance of a multidisci-
plinary team of oncologists, survey methodologists, genetic 
counselors, bioethicists, and health communication experts. 
Surveys were designed to minimize participant burden (ie, 
taking <30 minutes to complete).
2.4.1 | Patient characteristics
Demographic characteristics (eg, age, gender, and level of 
education) were assessed via standard self‐report question-
naire items. We gathered information about the patient's can-
cer (type, stage) from the PMTB test report. A single survey 
item asked participants to rate their current level of distress 
on a 0‐10 scale (10 being highest).
2.4.2 | Motivations and concerns regarding 
study participation
We assessed motivations for study participation by posing 
nine reasons why cancer patients might participate in genome 
sequencing and asking participants to indicate how much they 
agreed or disagreed (1 = strongly disagree to 4 = strongly 
agree) with each statement. Items encompassed reasons in-
cluding potential direct clinical benefits, altruism, and social 
network pressure. Participants also identified which item re-
flected their main reason for joining the study. We gener-
ated an overall index of motivations for study participation 
by summing items (possible range: 9‐36, with higher scores 
indicating higher levels of motivation), with a subscale con-
sisting of items related to direct clinical benefits. This scale 
demonstrated good reliability in the current study, with a 
Cronbach alpha score of 0.81.
Concerns about study participation were assessed via 
six items asking participants to rate their level of concern 
(1 = not at all to 5 = extremely) about potential negative 
F I G U R E  1  Study flowchart. RR, 
response rate
Patients consented to surveys: 393
Non-responder: 77 Completed Survey: 297 (RR: 79.4%)
Patients eligible for baseline survey: 374  
Patients eligible for follow-up survey: 285 
No sequencing or tumor 
content too low for 
reporting: 41 
Deceased or hospice: 41 
Declined participation: 7
Completed Surveys: 
217 (RR: 76.1%) Non-responder: 68
Deceased or hospice: 19 
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aspects of study participation. Items addressed issues includ-
ing lack of direct benefit from sequencing results and distress 
from learning genomic information.
2.4.3 | Knowledge
Baseline study surveys assessed patients’ objective and sub-
jective knowledge of genome sequencing, including how it 
would be employed in the MI‐ONCOSEQ project.
Knowledge of genome sequencing (objective)
We adapted a general knowledge of genome sequencing 
scale14 for use in a cancer population. Six true/false items 
assessed knowledge of basic facts about genome sequencing, 
including its potential benefits and limitations. We created 
an overall knowledge score by summing correct responses to 
scale items (possible range: 0‐6, with higher scores indicating 
greater knowledge).
Knowledge of informed consent (subjective)
We adapted an existing measure assessing the quality of in-
formed consent in clinical cancer research15 for use in this 
study. Six items asked participants to rate how well they 
understood (1 = “I did not understand this at all” to 5 = “I 
understood this very well”) different aspects of the MI‐
ONCOSEQ research project, including study purpose, pro-
cedures, and risks and benefits. Items were summed to create 
an overall measure of subjective understanding of informed 
consent (possible range: 6‐30 with higher scores indicating 
higher level of understanding). The scale demonstrated good 
reliability in the current study, with a Cronbach alpha score 
of 0.88.
Knowledge of study's return of results policies 
(objective)
We assessed participants’ knowledge of genomic results to 
be returned to them in the MI‐ONCOSEQ project using a 
novel 10‐item scale. Participants received a list of possible 
types of genome sequencing results and indicated whether or 
not they would receive such results as part of their study par-
ticipation. Response options included “I would receive these 
results automatically,” “I would only receive these results if I 
said I wanted them”, “I would not receive these results,” and 
“Not sure.” We created an overall knowledge score by sum-
ming correct responses to scale items (possible range: 0‐10, 
with higher scores indicating greater knowledge).
2.4.4 | Expectations of study benefits
An 8‐item measure, administered at baseline, assessed pa-
tients’ expectations regarding potential study benefits. 
Questions asked participants about the extent to which they 
agreed (1 = strongly disagree to 4 = strongly agree) with 
various statements expressing expectations for study par-
ticipation. Items addressed what type of information they 
expected to gain from sequencing, how they expected the 
results to be communicated, and potential outcomes such 
as clinical trial enrollment. The follow‐up survey posed the 
same eight items, and participants were asked whether or not 
the outcome described in the survey item had occurred (re-
sponse options included: “yes,” “no,” or “unsure”). For the 
baseline survey, we summed items to create an overall meas-
ure of expectations of study benefits (possible range: 8‐32, 
with higher scores indicating higher levels of expectation). 
The scale demonstrated good reliability in the current study, 
with a Cronbach alpha score of 0.83.
2.4.5 | Decisional satisfaction
In the follow‐up survey, we administered two items from a 
validated measure of decisional satisfaction16 to assess par-
ticipants’ satisfaction with (vs regret about) their decision 
to participate in the MI‐ONCOSEQ project. Items asked 
whether participants would undergo genome sequencing if 
they had the choice to do it again (1 = strongly disagree to 
5 = strongly agree), and the extent to which they were satis-
fied with their decision to participate in the study (1 = not at 
all to 5 = extremely).
2.5 | Data analysis
Descriptive statistics were used to (a) characterize the study 
sample in terms of its demographics and other characteristics 
and (b) report on item‐level responses across study measures 
including motivations and concerns regarding study partici-
pants, knowledge of return of results policies, and expecta-
tions regarding study benefits. Within‐subject analyses were 
performed for comparison of baseline and follow‐up survey 
responses on the benefit expectations measure, using only 
data from the 205 respondents who had completed these sur-
vey scales at both time points.
In post hoc analyses, we performed stepwise binary logis-
tic regression using the forward logistic regression method 
(forward LR) for including variables in the model to assess 
predictors of key study outcomes including motivations for 
study participation, expectations of direct study benefits, and 
knowledge of study policies regarding return of results, with 
statistical significance assessed at P < 0.05. Each model 
contained seven predictors as follows: genomic sequencing 
knowledge, informed consent understanding, and psycholog-
ical distress (measured at baseline), as well as age, gender 
(female or male), self‐reported race (white or non‐white), ed-
ucation (three categories: high school or less, some college, 
or college or greater). We excluded from analysis participants 
with missing values on the outcome measures or key covari-
ates (<5%). Given the non‐normal distribution of scores on 
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study outcome measures, we used a median split procedure 
to dichotomize scale scores for the following variables: 
motivations for study participation, expectations of direct 
study benefits, and knowledge of study policies regarding 
return of results. Logistic regression analyses yielded odds 
ratios reporting the odds of scoring in the higher vs lower 
group on motivations, expectations, and knowledge outcome 
measures.
3 |  RESULTS
3.1 | Sample characteristics
Characteristics of the study sample are presented in Table 1. 
In brief, the sample was predominantly white (93.6%), mid-
dle aged (mean age = 57.9 years), and well‐educated (81.5% 
with at least some college education), with a roughly equal 
number of men and women (51% male vs 49% female). 
Patients’ cancer diagnoses included >20 types of cancer, 
with breast (n = 50) and prostate (n = 36) cancer as the most 
common types (see Figure 2 for more details).
3.2 | Motivations and concerns regarding 
study participation
Participants endorsed a range of motivations for study partici-
pation (see Table 2), including desire to contribute to cancer 
research, to assist future cancer patients, and to potentially ob-
tain direct study benefits pertaining to their own cancer treat-
ment and identification of genetic cancer risks in blood relatives. 
When asked what their main reason was for study participation, 
about half of the participants endorsed items related to advanc-
ing the field of cancer research. For example, 29% endorsed 
“to help researchers better understand my type of cancer,” and 
21% endorsed “to contribute to cancer research.” Nearly 40% of 
participants cited a main reason related to direct study benefits 
for themselves or family members. For example, 30% endorsed 
“to see if my sequence results could help make treatment deci-
sions for me,” 6% endorsed “to gain information relevant for the 
health of my biological relatives,” and 3% endorsed “to have 
more certainty about my type of cancer.”
Most participants did not endorse strong concerns about 
the potential risks of study participation (see Table 2). Fewer 
than 10% of participants indicated they were extremely con-
cerned about potential study risks including increased anx-
iety and receipt of unwanted genetic information. The most 
commonly endorsed concern was that sequencing results 
would not be informative for the patient's own cancer treat-
ment, with 13% reporting they were “extremely concerned” 
about this possible study outcome.
In an adjusted multivariable model, patients with at least a 
college degree had lower odds than those with a high school ed-
ucation of reporting that direct benefits of study participation 
were a study motivation (OR = 0.44, 95% CI: 0.22‐0.96, 
P = 0.040). Higher self‐reported level of understanding of the 
informed consent process was also significantly associated with 
higher odds of endorsing direct benefits as motivation for study 
participation (OR = 1.09, 95% CI: 1.05‐1.18, P = 0.001).
T A B L E  1  Sample characteristics (N = 297)
Characteristics n (%)
Mean age, y (SD) 59.1 (12.0)
Range 20‐85
Gender
Male 148 (50.2%)
Female 147 (49.8%)
Race/ethnicity
White 285 (96.0%)
Black 3 (1.0%)
Other 5 (1.7%)
Highest level of education
High school or less 55 (18.5%)
Some college 103 (34.7%)
College graduate or greater 139 (46.8%)
Mean psychological distress (0‐10 scale), SD 4.1 (2.7)
F I G U R E  2  Cancer types and frequencies among study 
participants
Lung cancer
Breast cancer
Soft tissue sarcoma
Hepatobiliary cancer
Prostate cancer
Cancer of unknown primary
Esophagogastric cancer and GIST
Bladder cancer
Head and neck cancer
Melanoma
Brain cancer
Colorectal cancer
Thyroid cancer
Ovarian cancer 
Salivary gland cancer
Pancreatic cancer
Bone cancer
Skin cancer, Non-melanoma
Others
Adrenocortical carcinoma
Renal cell carcinoma
Uterine sarcoma
10
2
 9
36
50
  13
 8
35
 10
  7 4
5
 2
3   9
20
 22
  7
 3
11
21
10
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3.3 | Knowledge of genome sequencing and 
study informed consent process
Participants demonstrated generally good overall knowledge of 
basic facts about genome sequencing, with an average score of 
5.3 (SD = 0.99) out of six items (88%) correct on a validated 
measure of genome sequencing knowledge. The vast majority of 
participants recognized that identification of cancer genes does 
not always lead to prevention or cure (96% correct), sequencing 
could give people information about disease risks beyond cancer 
(89% correct), and that sequencing results cannot provide exact 
estimates of cancer risk (85% correct). The survey item most 
often answered incorrectly was “sequencing all cancer genes is a 
routine test that doctors can order for most people with cancer,” 
with 17% of respondents erroneously endorsing as true.
Participants varied in the degree to which they reported 
understanding different aspects of the study's informed con-
sent process. Higher levels of subjective understanding were 
reported regarding study risks and benefits, with 55%‐60% 
of participants indicating that they understood these study 
elements very well. Levels of subjective understanding were 
somewhat lower regarding study purpose and procedures. For 
example, participants reported the lowest levels of subjective 
understanding for what would happen to their biological sam-
ples after DNA sequencing was completed, with only 37.5% 
saying that they understood this very well. Overall, 44% said 
that they understood the study very well when they signed its 
consent form.
We identified significant gaps in understanding regarding 
the study's policies for return of genomic sequencing results 
(see Table 3). The mean score on this knowledge scale was 4.1 
(SD = 1.5) items out of 10 correct. In general, participants evi-
denced a bias toward assuming that all types of genome sequenc-
ing results would automatically be returned. This meant that 
the vast majority of participants incorrectly indicated that they 
would receive incidental sequencing results related to genetic 
risk of noncancerous conditions, as well as pharmacogenomic 
findings to inform medication use in noncancerous conditions.
Multivariate logistic regression indicated that patients who 
self‐reported higher levels of understanding of the informed 
consent process (vs those reporting lower levels of understand-
ing) had higher odds of demonstrating correct knowledge about 
study policies regarding return of research results (OR = 1.09, 
95% CI: 1.03‐1.15, P = 0.003). Table 4 presents full results for 
this and other regression models conducted as part of the study.
3.4 | Expectations of study benefits
The vast majority of participants endorsed survey items at base-
line indicating that they expected a wide range of potential study 
benefits, including written reports of sequencing findings (88%), 
discussions with physicians about the implications of sequencing 
T A B L E  2  Motivations and concerns regarding study participation (N = 297)
Motivations for joining study Disagree (%) Agree (%) Strongly agree (%) Most importanta (%)
To help researchers better understand how to treat my type of 
cancer
7 (2.4) 35 (11.8) 255 (85.9) 90 (30.3)
To see if my DNA sequencing results could help make cancer 
treatment decisions for me
10 (3.4) 63 (21.3) 223 (75.3) 86 (29.0)
To contribute to cancer research. 9 (3.0) 73 (24.6) 215 (72.4) 42 (14.1)
Because I feel like I am helping other cancer patients 12 (4.0) 82 (27.6) 203 (68.4) 17 (5.7)
To gain information that may be relevant to the health of my 
biological relatives
25 (8.5) 86 (29.0) 186 (62.6) 24 (8.1)
To have more certainty about my type of cancer 25 (8.5) 88 (29.7) 183 (61.8) 12 (4.0)
Because my doctor recommended the study 56 (18.9) 124 (41.9) 116 (39.2) 14 (4.7)
To learn about my genetic risk for diseases other than cancer 92 (27.3) 100 (33.7) 116 (39.1) 1 (0.3)
Because my family encouraged me to participate 122 (41.5) 111 (37.8) 61 (20.7) 0 (0)
Concerns about study participation (Scale: 1 = not at all to 5 = extremely concerned) Mean (SD)
The DNA sequencing results may not guide my current cancer treatment care 2.75 (1.4)
The DNA sequencing results could give unwanted information about my biological relatives’ risk of cancer 2.19 (1.3)
The DNA sequencing results might be confusing or difficult to understand 2.23 (1.3)
The DNA sequencing results could give me information about my risk for other conditions that I may not want to know 
about
2.08 (1.2)
The DNA sequencing results might lead my doctor(s) to recommend things that I don't want to do 1.98 (1.2)
The DNA sequencing results might make me worried or anxious 1.91 (1.2)
aFour (1.3%) individuals selected more than one “most important” motivation; seven (2.3%) individuals did not endorse a “most important” motivation. 
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results (92%), notifications of clinical trials for which they might 
be eligible (84%), and learning more about the causes of their 
own cancer (74%), as well as gene changes that might have im-
plications for their relatives’ cancer risk (93%). In an adjusted 
multivariable model, self‐reported higher level of understanding 
of the study's informed consent process was significantly associ-
ated with greater odds of endorsing direct benefits from study 
participation (OR = 1.14, 95% CI: 1.07‐1.21, P = 0.001).
In the follow‐up survey, many fewer participants indicated 
actually receiving such direct study benefits than had endorsed 
expecting them at baseline (see Figure 3). For example, only 
22% said they had been told about gene changes related to their 
relatives’ cancer risk, 26% had gotten a written summary report 
of results, 47% had learned about clinical trials for which they 
might be eligible, and 52% had discussed sequencing results 
with their doctor. These analyses only included participants who 
had responded to relevant items in both the baseline and follow‐
up surveys.
3.5 | Decisional satisfaction and regret
At follow‐up, participants indicated high levels of satisfac-
tion with their decision to take part in the genome sequenc-
ing study, with a mean score of 4.06 (SD = 1.1) on a 5‐point 
scale (1 = not at all to 5 = extremely satisfied). The vast ma-
jority of respondents also indicated that they would make the 
same choice to undergo sequencing if they had it to do over 
again (mean score = 4.37 (SD = 0.9) on 5‐point scale from 
1 = strongly disagree to 5 = strongly agree).
4 |  DISCUSSION
This longitudinal survey is one of the first and largest stud-
ies to examine patients’ understanding and expectations re-
garding the use of next‐generation sequencing in their own 
cancer treatment. Perhaps our most notable finding was an 
apparent mismatch between patients’ pretest expectations of 
direct benefits from cancer genome sequencing and their ac-
tual realization of such benefits. Patients reported expecting 
a wide range of potential benefits from study participation, 
including greater understanding of underlying causes of their 
cancer, genomic information of relevance to their family 
members’ health, and the ability to enroll in clinical cancer 
trials on the basis of their sequencing results. Although in 
some cases these expectations were fulfilled, in more cases 
they were not. Patients’ high levels of satisfaction with their 
decision to participate in the study and low overall levels of 
decisional regret suggest that such unfulfilled expectations 
were likely not highly harmful. Yet one can imagine scenar-
ios where unrealistically high patient expectations about the 
potential benefits of precision oncology studies (eg, to lead 
to life‐saving therapies for a terminal condition) could distort 
Survey items (type of result) Correct response N (% correct)
Results relevant for relatives’ risk of 
developing cancer
Would receive automatically or 
only if wanted
288 (97.7)
Results that show an increased risk for 
a different type of cancer
Would receive automatically or 
only if wanted
286 (96.6)
Results that could guide current cancer 
treatment
Would receive automatically 264 (89.2)
Results that provide information about 
response to cancer medication
Would receive automatically 234 (78.8)
Results that help to explain my cancer 
but do NOT guide treatment
Would receive automatically 231 (78.3)
Results that show an increased risk for 
noncancerous conditions that cannot 
be treated effectively (eg, 
Alzheimer's disease)
Would not receive 20 (6.8)
Results that show a virus (eg, HIV or 
HPV)
Would not receive 15 (5.1)
Results that provide information about 
response to noncancer medications
Would not receive 13 (4.4)
Results relevant for relatives’ risk of 
developing noncancerous conditions
Would not receive 12 (4.1)
Results that show an increased risk for 
noncancerous conditions that can be 
treated effectively (eg, diabetes and 
heart conditions)
Would not receive 11 (3.7)
T A B L E  3  Knowledge of study 
policies regarding return of individual 
research results (n = 297)
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medical decision making or result in significant distress 
when such benefits do not occur (see Zikmund‐Fisher17 for a 
case example). Such potential “therapeutic misconceptions” 
about clinical research are not unique to precision oncology 
studies, but they may be encouraged by high levels of enthu-
siasm about the promise of genomically tailored approaches 
as expressed by the scientific community, for‐profit com-
panies, and media coverage of the field.18 Knowledge and 
expectations were generally not associated with participants’ 
demographic characteristics (eg, age, gender, race), but they 
did correlate with how well participants felt they understood 
key aspects of the study.
T A B L E  4  Logistic regression analyses of participant characteristics associated with key study outcomes
Participant characteristics
Perceived expectations of study 
benefits
Study motivations (direct 
benefits subscale)
Knowledge of study RoR 
policies
OR 95% CI P‐value OR 95% CI P‐value OR 95% CI P‐value
Age 0.99 0.97 1.03 0.758 1.02 0.99 1.04 0.109 1.00 0.98 1.03 0.815
Gender
Female Ref Ref Ref ‐ Ref Ref Ref ‐ Ref Ref Ref ‐
Male 1.32 0.77 2.26 0.309 1.09 0.65 1.82 0.741 1.4 0.81 2.47 0.220
Race
White Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Non‐white 0.93 0.26 3.34 0.908 0.82 0.27 2.45 0.724 1.12 0.35 3.57 0.844
Education
High school or less Ref Ref Ref ‐ Ref Ref Ref ‐ Ref Ref Ref ‐
Some college 0.91 0.38 2.12 0.828 0.53 0.23 1.19 0.123 0.75 0.32 1.75 0.508
College graduate or greater 0.76 0.29 1.56 0.361 0.44 0.20 0.96 0.040 0.66 0.29 1.50 0.320
Genome sequencing 
knowledge
0.77 0.60 1.03 0.082 1.04 0.79 1.38 0.773 1.24 0.94 1.63 0.125
Informed consent 
understanding
1.14 1.07 1.21 0.001 1.09 1.05 1.18 0.001 1.09 1.03 1.15 0.003
Psychological distress 
(baseline)
0.94 0.85 1.03 0.201 0.99 0.91 1.09 0.547 0.98 0.89 1.08 0.678
Italicized figures refer to statistically significant results (P < .05). RoR, return of results.
F I G U R E  3  Expected vs realized study benefits. Survey items were considered endorsed if participants responded "agree" or "strongly agree" 
at baseline and "yes" at follow-up"
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Despite generally good knowledge about cancer genome 
sequencing in general, participants reported lack of aware-
ness about key aspects of this genomic sequencing study. 
For example, fewer than 40% said they understood well 
what would happen to their biological samples after DNA 
sequencing was completed. Given common practices (and 
even federal requirements) of biobanking DNA samples for 
future, unspecified research, it may be prudent to provide 
study participants greater detail about how their samples 
might be used in future studies. Some states’ experiences 
with biobanking of residual blood spots from newborn 
screening show how public trust in the research enterprise 
can be damaged when individuals discover that their bi-
ological samples are being used for research purposes of 
which they were initially unaware.19
Another area prone to potential misunderstanding in-
volves return of individual genomic research results. There 
has been considerable debate within the genomics research 
community about if, whether, and when study investigators 
have an obligation to disclose individuals’ genomic findings 
that are clinically or personally significant.20 In precision 
oncology research, practices have varied widely, with some 
studies not returning results at all, some disclosing only 
cancer‐specific findings, and others reporting on notable 
secondary findings (eg, germline findings suggesting high 
risk of inherited cardiovascular disorders).21 In this study, 
the policy was to return clinically significant findings from 
both germline and tumor sequencing that were cancer‐re-
lated, but not to return secondary findings for noncancer-
ous conditions. Yet most patients appeared to presume they 
would be notified of any clinically significant secondary 
findings, even for diseases such as diabetes and Alzheimer's 
disease. Such beliefs may reflect the fact that patients don't 
always make sharp distinctions between clinical research 
and clinical practice (where the tendency would be to dis-
close clinically significant secondary findings), as well as an 
underappreciation of the complexity and labor involved to 
“hunt” for genomic findings unrelated to the initial purpose 
of sequencing.22 In addition, many studies do not explicitly 
inform participants about return of results policies for the 
multiple different types of secondary findings that might be 
generated.
Study findings suggest several areas in which patient edu-
cation might be improved. One obvious point of intervention 
would be during informed consent processes where cancer 
genomic sequencing is taking place. It is worth pointing out 
that the misunderstandings observed in this study occurred 
despite a relatively well‐educated patient population and a 
consent process carried out by well‐trained study staff and 
genetic counselors. As many commentators have pointed 
out, informed consent processes for genomic research have 
often been overburdened.23,24 It is not wise to expect that a 
severely ill population—one undergoing many life stresses 
and medical procedures—is going to fully absorb in one en-
counter the highly complex material represented by most pre-
cision oncology studies. As such, we would recommend use 
of a variety of communication strategies, some of which we 
have begun to implement at our own site. These include cre-
ation of a one‐page “Frequently Asked Questions” sheet as 
take‐home material to accompany the lengthy study consent 
form, and use of sample vignettes and visual aids to clarify 
the flow of study procedures and likelihood of direct benefits 
related to clinical care. Decision aids could also be useful 
here, and online aids specific to genome sequencing have 
now been developed.25
Although our study highlighted areas for improvement 
in patient education, it should be noted that participants 
in the study showed good knowledge of many basic facts 
about cancer genomic sequencing. For example, most rec-
ognized that identification of cancer genes does not inev-
itably lead to prevention or cure, that sequencing could 
generate secondary findings related to noncancerous con-
ditions, and that sequencing results cannot provide highly 
precise estimates of cancer risk. Interestingly, the most 
commonly held misconception as assessed by our genome 
sequencing knowledge measure, as reported by nearly one 
in five respondents, was that cancer genome sequencing 
is a routine test within current clinical practice. Although 
literature on the ethical, legal, and social implications of 
genetic testing has often highlighted the potential harms 
of learning personal genetic information,26 relatively few 
patients in the study expressed concerns regarding the pos-
sibility of psychological distress or unwanted information 
as a result of undergoing sequencing. In fact, the most com-
mon concern of participants was that sequencing would not 
yield clinically useful findings, which seems well‐justified 
given that precision oncology studies have not yet demon-
strated general effectiveness of molecular profiling in can-
cer treatment.27
Our findings should be interpreted in light of several 
study limitations. The study sample of cancer patients 
was disproportionately white and college‐educated, lim-
iting generalizability of study results. Future research in 
this area should attempt to enroll patient populations with 
greater diversity in terms of race, ethnicity, and socio-
economic status. Another study limitation was that some 
key measures had either not been formally validated (eg, 
knowledge of study return of results policies) or were not 
administered in their entirety (eg, decisional regret), which 
may have introduced some measurement error into the as-
sessment of key outcomes. In addition, some commenta-
tors have noted that surveys such as ours that demonstrate 
participant desires for direct study benefits are not inher-
ently indicative of therapeutic misconception; they point 
out that patients can simultaneously hope that research 
participation will improve their own personal care while 
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recognizing that such clinical benefits are not the primary 
purpose of a given study.28
In conclusion, this study highlights the need for care-
ful communication with cancer patients considering the 
use of genome sequencing to inform their treatment plans. 
Clarifying the likelihood of clinical benefit from sequenc-
ing and the “what, when and how” of reporting sequencing 
results are essential to managing patient expectations and 
ensuring truly informed consent. As genome sequencing is 
increasingly incorporated in precision oncology, we must pay 
sufficient attention to the critical role that health communica-
tions can have in the patient experience.
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